ASXL1 and acute myeloid leukemia: In contrast, GSK-J4 treatment did not improve survival nor reduce disease burden in NSG mice xenografted with THP-1 or AML PDX #2 (ASXL1-WT) cells (Supplemental Figure 7, R–T).